US-based biopharmaceutical company Omeros has reported positive results from its ongoing Phase II clinical trial of OMS721 for the treatment of patients with hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HCT-TMA).

OMS721 is a human antibody of MASP-2, a new pro-inflammatory protein target involved in activation of a component of the immune system known as complement system.

The trial results from seven patients were found to be consistent with previously reported results and indicated statistically significant and clinically meaningful improvements such as mean platelet count, mean LDH and mean haptoglobin.

The uncontrolled Phase II trial is being conducted in patients with one of three types of TMA, including HCT-TMA.

The study is enrolling adult patients with post-transplant TMA persisting at least two weeks after the calcineurin inhibitor modification.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Omeros chairman and chief executive officer Gregory Demopulos said: “We are excited about the consistently positive results in this study.

"We are excited about the consistently positive results in this study."

“HCT-TMA is frequently fatal and there is no approved treatment. We plan to discuss our data with the FDA and international regulatory agencies as we continue to design an efficient Phase III programme, with the objective of accelerating access to OMS721 for physicians and their patients.”

The trial's primary efficacy endpoint is change in platelet count, while other efficacy endpoints include changes in lactate dehydrogenase (LDH) and haptoglobin levels.

Neither the adverse events reported nor the deaths that occurred during the course of the study are considered to be associated with OMS721 treatment.

The drug is being further evaluated in a Phase III trial for atypical hemolytic uremic syndrome and in another Phase II trial for glomerulonephropathies.

Image: Micrograph of thrombotic microangiopathy. Photo: courtesy of Nephron/Wikipedia.